Regulatory Advice and Novelty in Pharmaceutical Innovation

Lars Van Cutsem, Marleen Willekens and Koenraad Debackere

No 742967, Working Papers of Department of Management, Strategy and Innovation, Leuven from KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven

Abstract: This study conducts the first quasi-experimental evaluation of the effectiveness of regulatory advice to stimulate novel medicine development. Medicine development is subject to pharmaceutical standards for safety, efficacy and quality, ultimately serving public safety interests. Novel medicine development, however, often requires non-standard trial designs, surrogate (pre-)clinical endpoints, and specific post-authorisation risk management plans. Stringency in pharmaceutical standards subsequently disincentivizes particularly novel medicine development due to elevated difficulties and costs to demonstrate adherence to safety/efficacy standards. We use data on medicines authorised in the EU, and show that the use of regulatory advice services, intended to aid generating robust evidence of medicine safety and efficacy, increases the propensity to develop and successfully bring to market novel medicines. Notably, we show that regulatory advice services are particularly relevant for inexperienced firms.

Keywords: G074819N#54967485 (search for similar items in EconPapers)
Date: 2024
New Economics Papers: this item is included in nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
https://lirias.kuleuven.be/retrieve/763334 Accepted version (application/pdf)
KU Leuven intranet only, request a copy at https://lirias.kuleuven.be/handle/20.500.12942/742967

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ete:msiper:742967

Access Statistics for this paper

More papers in Working Papers of Department of Management, Strategy and Innovation, Leuven from KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven
Bibliographic data for series maintained by library EBIB ().